Medpace tightens discount on $530 million term loan to 99½

By Sara Rosenberg

New York, March 27 - Medpace Inc. modified the original issue discount on its $530 million seven-year covenant-light term loan to 99½ from 99, according to a market source.

Pricing on the loan is still Libor plus 400 basis points with a 1% Libor floor, but a step-down was added to Libor plus 375 bps when leverage is 4.75 times, the source said.

As before, the term loan has 101 soft call protection for six months.

The company's $590 million credit facility (B2/B+) also includes a $60 million revolver.

Jefferies Finance LLC, Barclays, Credit Suisse Securities (USA) LLC, UBS Securities LLC and Wells Fargo Securities LLC are the lead banks on the deal.

Proceeds will be used to help fund the buyout of the company by Cinven from CCMP Capital.

Medpace is a Cincinnati-based full-service clinical research organization providing phase 1-4 core development services for drug, biologic and device programs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.